Cancer Cell Diagnostics Launches CellSight™ DNA Comprehensive Genomic Profiling Test to Advance Precision Oncology
Cancer Cell Diagnostics (CCDx) has announced the commercial launch of CellSight™ DNA, its next-generation comprehensive genomic profiling (CGP) assay designed to provide oncologists with a broader and more detailed understanding of tumor genetics from a simple blood sample. Unlike conventional liquid biopsy technologies that rely on fragmented circulating tumor DNA (ctDNA), CellSight™ DNA is built on a fundamentally different scientific approach that isolates intact circulating tumor cells (CTCs), enabling direct genomic analysis from whole cancer cells.
The introduction of CellSight™ DNA marks a significant milestone for the company as it expands its precision oncology portfolio and introduces a new platform designed not only for comprehensive DNA sequencing but also for future multiomic applications. By preserving entire circulating tumor cells, the CellSight™ platform has the potential to extend beyond traditional genomic profiling into RNA analysis, protein characterization, functional assays, and integrated molecular diagnostics.
A New Direction for Liquid Biopsy Technology
Liquid biopsy has transformed cancer diagnostics over the past decade by allowing physicians to evaluate tumor genetics through a routine blood draw rather than invasive tissue biopsies. Most commercially available liquid biopsy tests analyze circulating tumor DNA—small fragments of genetic material released into the bloodstream as cancer cells die.
Although ctDNA testing has become an important tool for identifying actionable mutations, monitoring disease progression, and guiding treatment decisions, the technology has inherent limitations. Since ctDNA consists of fragmented DNA released from dying tumor cells, the quantity and quality of genetic material can vary significantly depending on tumor type, disease burden, and biological factors.
Cancer Cell Diagnostics has developed CellSight™ DNA to overcome some of these limitations by focusing on intact circulating tumor cells instead of fragmented DNA.
Circulating tumor cells are living cancer cells that detach from primary or metastatic tumors and travel through the bloodstream. Because these cells remain structurally intact, they contain the complete genomic information of the tumor, providing researchers and clinicians with access to a richer source of biological data.
Proprietary Technology Targets Whole Tumor Cells
At the core of the CellSight™ platform is Cancer Cell Diagnostics’ proprietary, patent-pending enrichment technology that selectively isolates circulating tumor cells from a standard blood sample.
Following isolation, DNA is extracted directly from these intact cells rather than from free-floating DNA fragments. This approach allows comprehensive genomic analysis while preserving additional biological material for future testing.
According to the company, the ability to recover whole tumor cells creates opportunities that extend far beyond DNA sequencing alone.
Unlike conventional ctDNA assays, which consume fragmented genetic material during analysis, CellSight™ preserves intact cells that may later be used for complementary molecular investigations.
This creates a flexible platform capable of evolving alongside advances in cancer biology and precision medicine.
Comprehensive Genomic Profiling from a Single Blood Draw
CellSight™ DNA performs broad genomic profiling using next-generation sequencing technology.
The assay analyzes more than 500 cancer-associated genes, enabling clinicians to identify multiple classes of genomic alterations that may influence diagnosis, prognosis, treatment selection, and clinical trial eligibility.
The comprehensive panel includes detection of:
- Single nucleotide variants (SNVs)
- Insertions and deletions (indels)
- Copy number variations (CNVs)
- Microsatellite instability (MSI)
- Tumor mutational burden (TMB)
By evaluating these diverse genomic biomarkers within a single assay, CellSight™ DNA aims to provide physicians with a comprehensive molecular portrait of each patient’s cancer.
Such information can support personalized treatment planning and help identify targeted therapies or immunotherapies that may be appropriate based on the tumor’s genetic profile.
Company Highlights Advantages of Whole-Cell Analysis
Tifiny McDonald, Chief Executive Officer of Cancer Cell Diagnostics, emphasized that the company’s technology represents a fundamentally different approach to cancer genomic profiling.
She explained that CellSight™ DNA profiles more than 500 genes while simultaneously reporting tumor mutational burden and microsatellite instability from a single blood draw.
Unlike conventional liquid biopsy assays that analyze fragmented circulating tumor DNA, the CellSight™ platform is designed to generate genomic information directly from intact circulating tumor cells.
According to McDonald, this approach enables oncologists to obtain a more comprehensive understanding of tumor biology while also preserving valuable biological material for future analyses beyond DNA sequencing.
She noted that because whole tumor cells are recovered, the company has established a foundation for expanding the platform into additional molecular applications as scientific understanding continues to advance.
Supporting Precision Oncology
Precision oncology increasingly depends on comprehensive molecular profiling to guide individualized treatment decisions.
As the number of targeted therapies continues to expand across multiple cancer types, physicians require increasingly detailed genomic information to identify patients most likely to benefit from specific treatments.
Comprehensive genomic profiling has become particularly valuable for patients with advanced cancers, recurrent disease, or tumors lacking clear therapeutic options.
By providing broad genomic characterization from a minimally invasive blood sample, CellSight™ DNA may offer an alternative option when tissue biopsy is unavailable, insufficient, or difficult to obtain.
Repeated blood-based testing may also facilitate longitudinal monitoring of tumor evolution during treatment.
Analytical Performance Demonstrates Strong Validation
Cancer Cell Diagnostics reported encouraging analytical validation data supporting the performance of CellSight™ DNA.
Under established standard operating procedures, the assay demonstrated:
- A limit of detection of 5% for single nucleotide variants.
- Analytical sensitivity greater than 99%.
- Positive predictive value exceeding 97%.
- Successful qualitative detection of representative insertions and deletions across tested samples.
These validation results indicate that the assay can reliably detect clinically relevant genomic alterations with high analytical accuracy.
While additional clinical validation and real-world experience will further define the assay’s clinical utility, the reported analytical performance provides a strong foundation for commercial implementation.
CLIA-Certified Laboratory Operations
All CellSight™ DNA testing is performed within Cancer Cell Diagnostics’ CLIA-certified laboratory located in Jupiter, Florida.
Operating within a CLIA-certified environment ensures that laboratory procedures comply with federal quality standards governing clinical testing.
The laboratory utilizes next-generation sequencing technologies combined with the company’s proprietary CTC enrichment platform to deliver comprehensive genomic profiling for oncology practices.
Platform Designed for Future Expansion
Although CellSight™ DNA represents the first commercial assay introduced on the CellSight™ platform, the broader technology was intentionally designed with future expansion in mind.
Because the enrichment process preserves intact circulating tumor cells, researchers can potentially perform multiple downstream analyses using the same sample.
Future applications may include:
- RNA sequencing
- Gene expression profiling
- Protein biomarker analysis
- Functional cellular assays
- Integrated multiomic testing
This versatility distinguishes CellSight™ from many existing liquid biopsy technologies that rely solely on fragmented DNA.
As molecular diagnostics continue evolving toward integrated genomic, transcriptomic, proteomic, and functional analyses, preserving intact tumor cells could provide substantial long-term value.
Advancing Multiomic Cancer Diagnostics
The oncology community increasingly recognizes that DNA mutations represent only one component of tumor biology.
Gene expression patterns, protein signaling pathways, immune interactions, and cellular function all contribute to treatment response and disease progression.
Multiomic approaches seek to integrate these complementary data sources into a more comprehensive understanding of cancer.
Cancer Cell Diagnostics believes its whole-cell platform creates a natural foundation for these future diagnostic capabilities.
Rather than requiring separate samples for different testing modalities, preserved circulating tumor cells could support multiple analyses from a single blood collection.
This streamlined workflow may eventually simplify testing while generating richer biological insights.
Potential Clinical Applications
As additional assays are developed, the CellSight™ platform may support numerous clinical applications across oncology.
Potential future uses include:
- Comprehensive molecular profiling for precision medicine
- Identification of actionable therapeutic targets
- Selection of targeted therapies
- Immunotherapy biomarker assessment
- Longitudinal monitoring of treatment response
- Detection of emerging resistance mutations
- Disease progression monitoring
- Clinical trial enrollment support
- Multiomic biomarker discovery
These capabilities align with the growing movement toward personalized cancer care based on comprehensive molecular characterization.
The commercial launch of CellSight™ DNA represents an important milestone for Cancer Cell Diagnostics as the company introduces an innovative approach to blood-based cancer genomic profiling. By shifting the focus from fragmented circulating tumor DNA to intact circulating tumor cells, the company aims to provide clinicians with a more complete view of tumor biology while creating opportunities for future expansion into RNA, protein, functional, and multiomic analyses.
With a comprehensive panel covering more than 500 genes, assessment of tumor mutational burden and microsatellite instability, strong analytical validation data, and testing performed in a CLIA-certified laboratory, CellSight™ DNA enters the precision oncology market as a differentiated genomic profiling platform.
As cancer diagnostics continue to evolve toward increasingly integrated molecular testing, Cancer Cell Diagnostics’ emphasis on preserving whole circulating tumor cells positions the CellSight™ platform to support both current clinical needs and the next generation of precision medicine innovations.
About Cancer Cell Diagnostics (CCDx)
Cancer Cell Diagnostics is a precision oncology company based in Jupiter, Florida. Its CellSight™ platform isolates intact circulating tumor cells from peripheral blood, enabling comprehensive genomic profiling and downstream molecular and multiomic analyses. Operating a CLIA-certified laboratory, the company is focused on offering clinicians a more complete molecular understanding of each patient’s cancer. Learn more at cancercelldx.com.
CellSight™ DNA is a laboratory-developed test. It has not been cleared or approved by the U.S. Food and Drug Administration.